Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 14.48% is 544% above its 5-year average of 2.25%, near the high end of its 5-year range (-4.88%–14.48%).
As of the fiscal period ended Tuesday, June 30, 2026. 438.30% above its 12-month average of 2.69%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 14.48%.
RETURN ON INVESTED CAPITAL (ROIC)
14.48%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
2.69%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
3.65%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
2.25%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
5.99%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
6.91%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
7.12%
CURRENT VS TTM AVG
+438.30%
CURRENT VS 3Y AVG
+297.19%
CURRENT VS 5Y AVG
+543.64%
CURRENT VS 10Y AVG
+141.83%
CURRENT VS 15Y AVG
+109.57%
CURRENT VS 20Y AVG
+103.24%
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
+140.62%
vs the sector median at left
Jazz Pharmaceuticals plc
Market Cap
$14.54B
Return on Invested Capital (ROIC)
14.48%
TTM Avg
2.69%
3Y Avg
3.65%
5Y Avg
2.25%
Market Cap
$14.63B
Return on Invested Capital (ROIC)
13.20%
TTM Avg
11.64%
3Y Avg
9.77%
5Y Avg
9.10%
Market Cap
$14.66B
Return on Invested Capital (ROIC)
37.87%
TTM Avg
23.96%
3Y Avg
17.78%
5Y Avg
13.78%
Market Cap
$14.69B
Return on Invested Capital (ROIC)
7.72%
TTM Avg
5.13%
3Y Avg
6.33%
5Y Avg
6.84%
Market Cap
$14.04B
Return on Invested Capital (ROIC)
5.85%
TTM Avg
-27.36%
3Y Avg
-53.87%
5Y Avg
-49.45%
Market Cap
$15.07B
Return on Invested Capital (ROIC)
15.85%
TTM Avg
12.30%
3Y Avg
11.68%
5Y Avg
11.64%
Market Cap
$13.81B
Return on Invested Capital (ROIC)
-134.14%
TTM Avg
-137.40%
3Y Avg
-154.30%
5Y Avg
-138.87%
Market Cap
$13.11B
Return on Invested Capital (ROIC)
-62.14%
TTM Avg
-81.52%
3Y Avg
-104.01%
5Y Avg
-93.27%
Market Cap
$13.01B
Return on Invested Capital (ROIC)
27.42%
TTM Avg
23.21%
3Y Avg
18.97%
5Y Avg
21.23%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc (JAZZ) | $14.54B | 14.48% | 2.69% | 3.65% | 2.25% |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 13.20% | 11.64% | 9.77% | 9.10% |
| Exelixis, Inc. (EXEL)vs › | $14.66B | 37.87% | 23.96% | 17.78% | 13.78% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | 7.72% | 5.13% | 6.33% | 6.84% |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | 5.85% | -27.36% | -53.87% | -49.45% |
| Solventum Corporation (SOLV)vs › | $15.07B | 15.85% | 12.30% | 11.68% | 11.64% |
| Summit Therapeutics Inc. (SMMT)vs › | $13.81B | -134.14% | -137.40% | -154.30% | -138.87% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | -62.14% | -81.52% | -104.01% | -93.27% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 27.42% | 23.21% | 18.97% | 21.23% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 0.87% | 11.88% | 15.16% | 18.34% |
ROIC
14.5%
ROE
19.6%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | 14.48% |
| 2026-03-31 | 4.64% |
| 2025-12-31 | 2.15% |
| 2025-09-30 | -4.88% |
| 2025-06-30 | -2.94% |
| 2025-03-31 | 5.75% |
| 2024-12-31 | 6.51% |
| 2024-09-30 | 5.76% |
| 2024-06-30 | 5.38% |
| 2024-03-31 | 5.00% |
| 2023-12-31 | 5.53% |
| 2023-09-30 | 1.88% |
| 2023-06-30 | 0.44% |
| 2023-03-31 | -0.27% |
| 2022-12-31 | -0.66% |
| 2022-09-30 | 2.57% |
| 2022-06-30 | 2.38% |
| 2022-03-31 | 0.87% |
| 2021-12-31 | 1.48% |
| 2021-09-30 | 1.37% |
| 2021-06-30 | 2.02% |
| 2021-03-31 | 9.74% |
| 2020-12-31 | 5.41% |
| 2020-09-30 | 4.51% |
| 2020-06-30 | 3.56% |
| 2020-03-31 | 4.31% |
| 2019-12-31 | 10.22% |
| 2019-09-30 | 12.69% |
| 2019-06-30 | 13.82% |
| 2019-03-31 | 11.38% |
| 2018-12-31 | 10.66% |
| 2018-09-30 | 11.03% |
| 2018-06-30 | 9.31% |
| 2018-03-31 | 9.69% |
| 2017-12-31 | 10.86% |
| 2017-09-30 | 9.14% |
| 2017-06-30 | 9.92% |
| 2017-03-31 | 9.90% |
| 2016-12-31 | 9.45% |
| 2016-09-30 | 8.37% |
| 2016-06-30 | 12.04% |
| 2016-03-31 | 12.19% |
| 2015-12-31 | 12.12% |
| 2015-09-30 | 11.84% |
| 2015-06-30 | 9.86% |
| 2015-03-31 | 8.39% |
| 2014-12-31 | 3.44% |
| 2014-09-30 | 2.81% |
| 2014-06-30 | 3.76% |
| 2014-03-31 | 3.81% |
| 2013-12-31 | 11.72% |
| 2013-09-30 | 15.76% |
| 2013-06-30 | 13.99% |
| 2013-03-31 | 12.80% |
| 2012-12-31 | 10.96% |
| 2012-09-30 | 5.87% |
| 2012-06-30 | 5.45% |
| 2012-03-31 | 10.50% |
| 2011-12-31 | 37.46% |
| 2011-09-30 | 71.67% |
| 2011-06-30 | 59.48% |
| 2011-03-31 | 56.05% |
| 2010-12-31 | 46.46% |
| 2010-09-30 | 76.20% |
| 2010-06-30 | 57.87% |
| 2010-03-31 | 39.19% |
| 2009-12-31 | 19.59% |
| 2009-09-30 | -70.38% |
| 2009-06-30 | -107.74% |
| 2009-03-31 | -204.63% |
| 2008-12-31 | -256.51% |
| 2008-09-30 | -152.11% |
| 2008-06-30 | -136.82% |
| 2008-03-31 | -97.39% |
| 2007-12-31 | -79.69% |
| 2007-09-30 | -83.16% |
| 2007-06-30 | -65.14% |
| 2007-03-31 | -59.65% |
| 2006-12-31 | -41.91% |
| 2005-12-31 | -40.40% |
